Celcuity Inc
CELC39.545USD
+1.045+2.71%
Market hours （ET）Quotes delayed by 15 min
1.50BMarket Cap
LossP/E TTM
More Details of Celcuity Inc Company
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Company Info
Ticker SymbolCELC
Company nameCelcuity Inc
IPO dateSep 20, 2017
Founded at2017
CEOMr. Brian F. Sullivan
Number of employees87
Security typeOrdinary Share
Fiscal year-endSep 20
Address16305 36th Ave N Ste 100
CityMINNEAPOLIS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code55446-4285
Phone17633920767
Websitehttps://www.celcuity.com/
Ticker SymbolCELC
IPO dateSep 20, 2017
Founded at2017
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.02M
+0.27%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
101.09K
--
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Mr. David F. Dalvey
Mr. David F. Dalvey
Independent Director
Independent Director
--
--
Dr. Charlotte Moser, M.D., Ph.D.
Dr. Charlotte Moser, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Leo T. Furcht, M.D.
Dr. Leo T. Furcht, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Brian F. Sullivan
Mr. Brian F. Sullivan
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.02M
+0.27%
Mr. Richard J. Nigon
Mr. Richard J. Nigon
Independent Director
Independent Director
101.09K
--
Ms. Vicky Hahne, CPA
Ms. Vicky Hahne, CPA
Chief Financial Officer
Chief Financial Officer
18.86K
+1.63%
Dr. Richard E. Buller, M.D., Ph.D.
Dr. Richard E. Buller, M.D., Ph.D.
Independent Director
Independent Director
7.71K
-0.64%
Dr. Polly A. Murphy, DVM, Ph.D.
Dr. Polly A. Murphy, DVM, Ph.D.
Independent Director
Independent Director
5.00K
--
Dr. Lance G. Laing, Ph.D.
Dr. Lance G. Laing, Ph.D.
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
Co-Founder, Chief Science Officer, Vice President, Secretary, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
10.94%
BVF Partners L.P.
8.91%
Sullivan (Brian F)
7.77%
Soleus Capital Management, L.P.
6.61%
Perceptive Advisors LLC
6.07%
Other
59.69%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
10.94%
BVF Partners L.P.
8.91%
Sullivan (Brian F)
7.77%
Soleus Capital Management, L.P.
6.61%
Perceptive Advisors LLC
6.07%
Other
59.69%
Shareholder Types
Shareholders
Proportion
Hedge Fund
37.76%
Investment Advisor
19.79%
Individual Investor
12.29%
Investment Advisor/Hedge Fund
10.89%
Private Equity
6.29%
Venture Capital
4.91%
Research Firm
1.98%
Corporation
0.92%
Pension Fund
0.09%
Other
5.09%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
212
36.06M
95.24%
-3.88M
2025Q1
215
36.05M
95.22%
-4.12M
2024Q4
205
35.54M
95.72%
-3.01M
2024Q3
191
34.97M
94.40%
-1.82M
2024Q2
174
33.96M
98.53%
+4.98M
2024Q1
164
26.84M
87.18%
+3.25M
2023Q4
146
21.83M
92.28%
-1.69M
2023Q3
148
21.82M
100.72%
+289.20K
2023Q2
156
20.45M
95.00%
-276.65K
2023Q1
152
18.61M
87.60%
-1.61M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
4.26M
11.24%
+1.58M
+58.96%
Mar 31, 2025
BVF Partners L.P.
3.47M
9.15%
--
--
Mar 31, 2025
Sullivan (Brian F)
3.02M
7.99%
+8.15K
+0.27%
Apr 14, 2025
Soleus Capital Management, L.P.
2.57M
6.8%
+9.04K
+0.35%
Mar 31, 2025
Perceptive Advisors LLC
2.36M
6.24%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.03M
5.35%
+10.04K
+0.50%
Mar 31, 2025
The Vanguard Group, Inc.
1.67M
4.42%
+20.26K
+1.23%
Mar 31, 2025
Eventide Asset Management, LLC
1.27M
3.34%
--
--
Mar 31, 2025
New Enterprise Associates (NEA)
1.25M
3.3%
--
--
Mar 31, 2025
Laing (Lance G Ph.D.)
1.25M
3.3%
--
--
Mar 17, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1%
iShares Genomics Immunology and Healthcare ETF
0.93%
ALPS Medical Breakthroughs ETF
0.37%
Tema Oncology ETF
0.26%
iShares Micro-Cap ETF
0.08%
iShares Russell 2000 Growth ETF
0.02%
iShares Russell 2000 ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1%
iShares Genomics Immunology and Healthcare ETF
Proportion0.93%
ALPS Medical Breakthroughs ETF
Proportion0.37%
Tema Oncology ETF
Proportion0.26%
iShares Micro-Cap ETF
Proportion0.08%
iShares Russell 2000 Growth ETF
Proportion0.02%
iShares Russell 2000 ETF
Proportion0.01%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
